Introduction: The diagnosis of Parkinson's disease is mainly clinical. DaT SCAN may help in difficult cases. Depression is also a clinical diagnosis and is common and persistent symptom in Parkinson's disease. Dementia is very often in Parkinson's disease, but usually not at the first stages. The treatment of each of the above symptoms is difficult and a lot of times individualized.
Introduction
The diagnosis of Parkinson's disease (PD) is, most of the times, clinical with sensitivity of 88% and specificity 78% [1, 2] . DaT SCAN may help in difficult cases [3, 4] . Depression is a common (up to 40%) and persistent symptom in Parkinson's disease [5, 6] . Depression is sometimes the first symptom of PD [7] . Other authors suggest that depression is a risk factor for PD [8] . The treatment of the depression in PD is difficult because of the lack of evidence [9] . Dementia also has high prevalence in Parkinson's disease [10] . Drug induced Parkinsonism should also be considered as a possible diagnosis. It is reported to be 20% of the patients with Parkinsonism [11] . It is well known that depression is associated with cognitive decline. Pseudodementia is a term that is usually used, but does not exist as an entity to any classification system. Furthermore depression has proved to be a risk factor for dementia and elderly patients with depression should have an ongoing monitoring for their cognitive function [12] .
Case Presentation
A 64 years old Caucasian female patient, education: 6 years, with history of hypothyroidism, depression, anxiety disorder and extrapyramidal symptoms was examined at our Memory and Dementia outpatient center on 26/1/2007. The patient had no suicidal thoughts, neither depressive symptoms. The MMSE score was 27, the FRSSD score was 0 and the Hamilton Scale score was 4. The UKPDS Brain Bank criteria are no longer fulfilled. The modified Hoehn and Yahr scale was at the stage 0, meaning no signs of disease.
Personal Past History
The patient had still no suicidal thoughts, neither depressive symptoms. Table 1 ).
The conclusion of the I-123-DaTSCAN was that these findings (rates out of the normal range for the Lenticular Nucleus) could not exclude the start of Parkinson's disease or the start of a mild extrapyramidal disorder.
On 28/11/2008, another I-123-DaTSCAN was performed with the following findings, which exclude Parkinson's disease and other Parkinsonian Syndromes ( Table 2) . The brain MRI which was performed on 29/1/2009 was almost normal according to her age (mild periventricular leukoencephalopathy).
Conclusion
An astonishing improvement occurred after the threat of life. The improvement is in functional cognitive and depressive symptoms. The parkinsonian symptoms also disappeared. The depressive symptoms remain in remission after a year and a half of follow up. One explanation is that the patient had Drug -Induced Parkinsonism-DIP-(Risperidon and Sulpiride), Drug induced dementia (Chlorimipramine Hydrochloride, Perphenazine/Amitriptyline hydrochloride-anticholinergic effect). On the other hand, DIP is dose-related [11] and Risperidon was given in a very low dose. Risperidon is also atypical antipsychotic, like Sulpiride which was also used previously for treating the patient. Another problem for the diagnosis of DIP is the findings of I-123-DaTSCAN on 16/1/2008 which support the diagnosis of Parkinson's disease. But this diagnosis was not clinically confirmed at the last visits, neither the 2 nd I-123-DaTS-CAN on 28/11/08 supported it. As far as the depression's remission, it is referred at the literature that depressed patients may experience significant relief of their depressive symptoms after the suicide attempt, but there is a high probability to undergo a relapse within a short period (3 months) [14] . In this case there is no relapse so far. (Two years after the suicide attempt). A close longitudinal follow up of the patient might give us more answers.
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